Policy
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
FEATURED STORIES
Policy initiatives have come fast and furious at the FDA this year. While guidances on rare diseases and vaccines have consumed most of the ink, policy shifts aimed at improving FDA efficiencies and reshoring U.S. manufacturing also got some attention. Here, BioSpace rounds up more than a dozen initiatives relevant to the biopharma industry.
With five CDER leaders in one year and regulatory proposals coming “by fiat,” the FDA is only making it more difficult to bring therapies to patients.
The record-setting government shutdown was just the latest blow to the U.S. biopharma industry. When science funding becomes a casualty of political gridlock, we lose valuable talent, erode public trust and jeopardize our position as a global leader in innovation.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Pfizer announced its RSV vaccine candidate PF-06482077 or RSVpreF, received Breakthrough Therapy designation from the U.S. Food and Drug Administration.
FibroGen is tangled up in a Securities Class Action Litigation and Derivative Litigation concerning clinical trial data for its drug Roxadustat.
Belgium-based Celyad Oncology voluntarily paused a clinical trial with Merck after two deaths. Getting CAR T therapies to work in solid tumors has proven to be a difficult challenge.
Throughout history, many different countries have had their biopharma supply chains changed – sometimes profitably, sometimes detrimentally – by war.
The National Brain Tumor Society is investing over $1 million in the DNA damage response consortium’s start. Here’s how this consortium will help researchers.
On Monday, Arbutus and Genevant filed a lawsuit against Moderna challenging patent infringement.
The decision was intended to resolve the matter as swiftly as possible so that those who claimed to have been harmed by the product could receive expeditious compensation.
It is unknown whether tightening economic sanctions will limit Russia’s ability to ship its vaccines to areas that do not have strong manufacturing capabilities.
Studies from Guttmacher Institute found that 54% of all abortions in the United States in 2020 were done with pills instead of surgery, an increase from approximately 44% in 2019.
Not only is this the first approval for a plant-based vaccine, it’s also the first approval for GSK’s adjuvant.